Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure

Cardiology Journal

Volumn 16, Issue 1, 2009, Pages 43-51

  Koç, Mevlüt ^a   Bozkurt, Abdi ^b   Şahin, Durmuş Yildiray ^b   Ünal, Ilker ^b   Acartürk, Esmeray ^b  

^a ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Cardiovascular events; Functional capacity; Heart failure; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FUNCTIONAL STATUS; HEART EJECTION FRACTION; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PROGNOSIS; REFERENCE VALUE; RELIABILITY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 60849087353     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol, 1996; 77: 828-831.
2. Passino C, Poletti R, Bramanti F, Prontera C, Clerico A, Emdin M. Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. Eur J Heart Fail, 2006; 8: 46-53.
3. Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV. N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: Linear correlation with exercise tolerance. Heart Lung Transplant, 2007; 26: 516-521.
4. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J, 2003; 24: 1735-1743.
5. Bayes-Genis A, Vazquez R, Puig T et al.; for the MUSIC Study Group. Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. Eur J Heart Fail, 2007; 9: 802-807.
6. Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin Chim Acta, 2006; 370: 174-179.
7. Eichhorn EJ. Prognosis determination in heart failure. Am J Med, 2001; 110 (suppl. 7A): 14S-36S.
8. Kotaska K, Popelova J, Tiserova M et al. NT-proBNP and BNP values in cardiac patients with different degree of left ventricular systolic dysfunction. Biomed Pap Med Fac, Univ Palacky Olomouc, Czech Repub, 2006; 150: 125-130.
9. Hartmann F, Packer M, Coats AJ et al. NT-proBNP in severe chronic heart failure: Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail, 2004; 6: 343-350.
10. Gardin JM, Adams DB, Douglas PS et al. Recommendations for a standardized report for adult transthoracic echocardiography: A report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr, 2002; 15: 275-290.
11. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr, 1989; 2: 358-367.
12. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation, 1977; 55: 613-618.
13. Rakowski H, Appleton C, Chan KL et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography. J Am Soc Echocardiogr, 1996; 9: 736-760.
14. Luchner A, Burnett JC Jr, Jougasaki M et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens, 2000; 18: 1121-1128.
15. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HB, Hildebrandt PR. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail, 2001; 3: 699-708.
16. Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriuretic peptide levels in systolic heart failure: Importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol, 2004; 43: 416-422.
17. Whalley GA, Gamble GD, Doughty RN. The prognostic significance of restrictive diastolic filling associated with heart failure: A meta-analysis. Int J Cardiol, 2007; 116: 70-77.
18. Patrianakos AP, Parthenakis FI, Papadimitriou EA et al. Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. Eur J Heart Fail, 2004; 6: 735-43.
19. The Criteria Committee of the New York Heart Association, Inc. Disease of the heart and blood vessels, nomenclature and criteria for diagnosis. 6th Ed. Little Brown, Boston 1964.
20. Bittner V. Determining prognosis in congestive heart failure: Role of the 6-minute walk test. Am Heart J, 1999; 138: 593-596.
21. Wilson JR, Hanamanthu S, Chomsky DB, Davis SF. Relationship between exertional symptoms and functional capacity in patients with heart failure. J Am Coll Cardiol, 1999; 33: 1943-1947.
22. Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Peak oxygen uptake better predicts outcome than submaximal respiratory data in heart transplant candidates. Circulation, 2000; 101: 1152-1157.
23. Myers J, Gullestad L, Vagelos R et al. Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Ann Intern Med, 1998; 129: 286-293.
24. Hogenhuis J, Jaarsma T, Voors AA, Hillege HL, Lesman I, van Veldhuisen DJ. Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. Int J Cardiol, 2006; 108: 63-67.
25. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): A new marker of cardiac impairment. Clin Endocrinol, 1997; 47: 287-296.
26. Harrison A, Morrison LK, Krishnaswamy P et al. B-type natriuretic peptide predicts future cardiac events in patients present ing to the emergency department with dyspnea. Ann Emerg Med, 2002; 39: 131-138.
27. McDonagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart, 2001; 86: 21-26.
28. Quińones MA, Greenberg BH, Kopelen HA et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: Significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol, 2000; 35: 1237-1244.
29. Richards AM, Doughty R, Nicholls MG et al; Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group, J Am Coll Cardiol, 2001; 37: 1781-1787.
30. Gardner RS, Chong V, Morton I, McDonagh TA. N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endotelin-1, adrenomedullin and tumor necrosis factor-α in patients referred for consideration of cardiac transplantation. Eur J Heart Fail, 2005; 7: 253-260.
31. Stanton E, Hansen M, Wijeysundera HC, Kupchak P, Hall C, Rouleau JL; PRAISE-2 study investigators. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart Fail, 2005; 7: 557-565.